Association between cardio-cerebrovascular disease and systemic antipsoriatic therapy in psoriasis patients using population-based data: A nested case-control study

The effect of antipsoriatic therapy on cardio-cerebrovascular disease (CCVD) is not well described. Thus, we performed a population-based nested case-control study to investigate the effect of systemic antipsoriatic therapy on CCVD in psoriasis patients. Using nationwide cohort data from the Korean...

Full description

Saved in:
Bibliographic Details
Published in:Journal of dermatology 2023-11, Vol.50 (11), p.1442-1449
Main Authors: Kim, Bo Ri, Lee, Kun Hee, Kim, Jinseob, Kim, Jee Woo, Paik, Kyungho, Myung, Woojae, Lee, Hyewon, Choi, Chong Won, Youn, Sang Woong
Format: Article
Language:English
Subjects:
Cerebral infarction
Cerebrovascular disease
Cerebrovascular diseases
Comorbidity
Diabetes mellitus
Dyslipidemia
Heart diseases
Hemorrhage
Ischemia
Myocardial infarction
Population-based studies
Psoriasis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The effect of antipsoriatic therapy on cardio-cerebrovascular disease (CCVD) is not well described. Thus, we performed a population-based nested case-control study to investigate the effect of systemic antipsoriatic therapy on CCVD in psoriasis patients. Using nationwide cohort data from the Korean National Health Insurance Claims database, newly diagnosed psoriasis patients were identified. Among the enrolled participants, postenrollment development of CCVD events (ischemic heart disease, myocardial infarction, cerebral infarction, and cerebral hemorrhage) was investigated. To evaluate the effect of systemic antipsoriatic therapy on CCVD risk, we calculated the proportion of the treatment period with systemic antipsoriatic therapy during the study period (PTP [%]: the sum of all systemic antipsoriatic therapy durations divided by total observation period). Among 251 813 participants, 6262 experienced CCVD events during the study period (CCVD group). Controls included 245 551 patients without CCVD history during the study period (non-CCVD group). The non-CCVD group had greater PTP than the CCVD group (CCVD 2.12 ± 7.92, non-CCVD 2.64 ± 9.64; P 
ISSN:0385-2407
1346-8138
DOI:10.1111/1346-8138.16904